Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Among 5153 decedents, 35.3% were in MA at death.
Why it matters
This study estimated how hospice use would differ if all Medicare beneficiaries were in Medicare Advantage. It found hospice use would be higher, especially among those with dementia, which concerns end-of-life care patterns rather than treating, curing or preventing Alzheimer's disease.
-
Stakeholder feedback led to substantive refinements, including delivery across six structured sessions, prioritisation of emotional safety and identity preservation, and explicit focus on carer‐mediated behaviour change.
Why it matters
This study describes the development of a psychosocial intervention called POST-ID for adults with intellectual disabilities after a dementia diagnosis, refined through caregiver feedback into six structured sessions and a co-produced support plan. It is an intervention development study and does not yet report outcomes on treating, curing, or preventing Alzheimer's disease.
-
This narrative review examines how socioeconomic disparities accelerate health decline in older adults.
Why it matters
This review reports that food insecurity and financial hardship are linked to poorer diet quality and increased risk of cognitive decline, among other outcomes. It suggests systemic approaches to food access may matter for health, but it does not test a treatment or cure for Alzheimer's disease.
-
Dementia risk is influenced by biological and lifestyle factors as well as broader socioeconomic conditions; however, the extent to which socioeconomic deprivation creates structural exposures that affect cognitive aging remains unclear.
Why it matters
Neighborhood deprivation was linked to dementia diagnosis in partially adjusted models, but this link was no longer significant after accounting for individual factors like education. This suggests neighborhood deprivation may not independently predict dementia risk.
-
41/100
The evidence for cognitive training in preventing cognitive decline in Alzheimer's disease is varied, with some studies indicating cognitive benefits but showing limited impact on functional outcomes or disease progression.
Why it matters
This review found that evidence for cognitive training in preventing cognitive decline in Alzheimer's disease is varied, with some cognitive benefits but limited impact on functional outcomes or disease progression. It does not show that cognitive training prevents or cures Alzheimer's disease.
-
Cognitive training shows potential in preventing cognitive decline in individuals at risk for Alzheimer's disease, especially as part of multimodal interventions, though current evidence varies in quality and clarity.
Why it matters
This review reports that cognitive training shows potential in preventing cognitive decline in people at risk for Alzheimer's disease, especially as part of multimodal interventions. However, it states that current evidence varies in quality and clarity, so no firm conclusion about prevention can be drawn.
-
Cognitive training appears effective in improving cognitive functions and delaying cognitive decline in people at risk of Alzheimer's disease but requires more standardized research for conclusive evidence.
Why it matters
This review reports that cognitive training appears effective in improving cognitive functions and delaying cognitive decline in people at risk of Alzheimer's disease. It states that more standardized research is required for conclusive evidence, so the effect is not yet firmly established.
-
Family caregivers of individuals with Alzheimer’s Disease and Related Dementia (AD/ADRD) face significant emotional and logistical challenges that place them at heightened risk for stress, anxiety, and depression.
Why it matters
Researchers built a GPT-4o-based chatbot called Carey and interviewed 16 family caregivers after scenario-driven interactions to learn what they need and expect from such tools. The findings are design insights for future AI systems, not evidence that a chatbot improves caregiver mental health.
-
Why it matters
This item is only a supplementary file with no summary or findings about Alzheimer's disease. It provides no information relevant to treating, curing, or preventing Alzheimer's disease.
-
Why it matters
This entry is only supplementary material with no summary or key findings provided. No information is available to describe what it means for treating, curing or preventing Alzheimer's disease.
-
Providing end-of-life care for patients with COPD, dementia, and cancer involves a focus on symptom management, integration of palliative care, and respecting patient preferences, while engaging families in the care process.
Why it matters
This review says end-of-life care for patients with coexisting COPD, dementia, and cancer involves symptom management, palliative care integration, respecting patient preferences, and engaging families. It notes that variability in practice and systemic challenges remain significant barriers to optimal care.
-
AWVs were associated with reduced risks for falls (HR: 0.976 for 2 AWVs; 0.936 for ≥3 AWVs) and fractures (HR: 0.978 for 1 AWV; 0.960 for 2 AWVs; 0.927 for ≥3 AWVs), with greater reductions observed with more AVWs.
Why it matters
In this study, more annual wellness visits were linked to lower risks of falls and fractures in older adults with Alzheimer's disease and related dementias, though the benefit was weaker for Black and rural residents. It supports wider use of wellness visits for prevention of falls and fractures, not a treatment or cure for the disease itself.
-
41/100
ACP is linked to lower EOL spending and a shift from inpatient to outpatient ADRD care; structured ACP delivery should be considered.
Why it matters
This retrospective cohort study of Medicare decedents with Alzheimer's disease and related dementias found that billed advance care planning was associated with lower end-of-life expenditures and reduced inpatient but greater outpatient use. It concerns healthcare utilisation and costs, not treating, curing or preventing Alzheimer's disease.
-
In both adolescents and adults with SUD, approximately 95% did not perceive a need for treatment.1 Although drug-related overdose deaths are declining, over 98,000 American deaths occurred in 2024.2 The vast majority of drug overdose deaths involve unregulated opioids, and in 2022 roughly 6.1 million people had an opioid use disorder (OUD) in the prior year.1 Costs related to the consequences of substance use the United States were nearly $1.5 trillion in 2020, up 37% from $1.07 trillion in 2017.3,4 Unhealthy substance use and untreated SUD may increase the risk of significant comorbid chronic health conditions, death from overdose, or suicide.
Why it matters
This statement describes the pharmacist's role in substance use disorder prevention, treatment, and recovery, including overdose deaths, opioid use disorder, and access to care. It does not report any treatment, cure, or prevention for Alzheimer's disease.
-
Appendix B. Coding tree of main categories and specific sub categories describing factors influencing readiness for advance care planning among people with dementia, family caregivers, and healthcare professionals.
Why it matters
This appendix presents a coding tree of categories and subcategories describing factors that influence readiness for advance care planning among people with dementia, family caregivers, and healthcare professionals. It contains no testing of any treatment, so it offers no information on treating, curing, or preventing Alzheimer's disease.
-
Appendix A. Interview guides on experiences with advance care planning, factors influencing readiness for advance care planning, and the use of conversation aids among people with dementia, family caregivers, and healthcare professionals.
Why it matters
This appendix provides the interview guides used to explore experiences with advance care planning, factors influencing readiness for it, and the use of conversation aids among people with dementia, family caregivers, and healthcare professionals. It reports no treatment or outcome results, so it offers no information on treating, curing, or preventing Alzheimer's disease.
-
Socioeconomic disadvantage is recognized as a risk factor for cognitive decline, yet its associated neural pathways remain unclear.
Why it matters
Higher neighborhood disadvantage was associated with poorer cognitive performance and smaller brain volumes in cognitively unimpaired older adults, with weaker associations in mild cognitive impairment and none in Alzheimer's disease. It describes associations with brain structure and cognition, not any treatment, cure, or prevention.
-
Artificial intelligence and neuroimaging enable accurate dementia prediction but often involve 'black box' models that can be difficult to trust.
Why it matters
Models trained on T1-weighted MRI reached balanced accuracies of 81% for Alzheimer's disease diagnosis and 67% for predicting conversion from mild cognitive impairment to all-cause dementia, and explainability methods highlighted brain regions relevant to Alzheimer's disease. This is diagnostic and prognostic research, not a treatment, cure, or prevention.
-
Hypertension remains a leading modifiable risk factor for cardiovascular and renal conditions and dementia.
Why it matters
This review covers AI used in diagnosing, monitoring, and predicting outcomes in hypertension, which is described as a modifiable risk factor for dementia. It does not test any treatment, cure, or prevention for Alzheimer's disease itself.
-
Misconceptions were common: 38% of participants equated ACP exclusively with decisions to forgo active treatment, and many conflated ACP with current rather than future-oriented care planning.
Why it matters
This cross-sectional study found that misconceptions about advance care planning were common in Japan, and that a dementia diagnosis alone reduced respect for patient preferences in 27.8% of cases. It suggests that policies have moved faster than healthcare professionals' ethical and legal understanding, so education is needed for advance care planning to genuinely safeguard patients' rights.
-
Carers' knowledge about dementia was moderate overall, with higher scores among those with greater education and previous dementia exposure.
Why it matters
This multi-center study in Thailand found family carers' dementia knowledge was moderate, with gaps about reversibility and behavioral management, and inconsistent hospital dementia-friendly practices. It concerns carer knowledge and hospital care, not a treatment or cure for Alzheimer's disease.
-
Among PWD with Medicaid, out-of-pocket costs for nursing homes and assisted living facilities were significantly higher (60%) compared to those TM (33%) and MA (30%).
Why it matters
Mean annual out-of-pocket costs for people with dementia were $4,590 in Traditional Medicare, $2,990 in Medicare Advantage and $2,900 in Medicaid, with different spending patterns by insurance type. This is about the financial burden of care, not about treating, curing or preventing Alzheimer's disease.
-
Medicare-funded home health care (HH) is a crucial resource helping Persons with Dementia (PwD) meet their care needs while aging in place.
Why it matters
This study found that after Medicare's new home health payment system began, people with dementia had lower odds of receiving nursing, occupational therapy, social work and aide services. It concerns access to home health care, not treating, curing or preventing Alzheimer's disease.
-
Of the 193,834 community-dwelling people with a new diagnosis of dementia, around 20% belonged to each material deprivation category.
Why it matters
This study found differences by socioeconomic status in hospital use, emergency visits, potentially inappropriate medications and mortality among people with a new dementia diagnosis, and suggests likely under-diagnosis in more deprived areas. It is about health inequities in care, not about treating, curing or preventing Alzheimer's disease.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Risk of Continued Institutionalization After Hospitalization in Older Adults
- Plasma metabolic profiles predict future dementia and dementia subtypes: a prospective analysis of 274,160 participants
- Prognostic significance of delirium in frail older people
- 3D-CAM: derivation and validation of a 3-minute diagnostic interview for CAM-defined delirium: a cross-sectional diagnostic test study
- Geographic Variation of Antidementia and Antipsychotic Medication Use Among US Nursing Home Residents With Dementia
- Palliative care for advanced dementia: Knowledge and attitudes of long-term care staff
- Screening for cognitive impairment in multiple sclerosis. An evaluation of the Mini-Mental State Examination
- Endoscopic characterization of oropharyngeal dysphagia in patients with dementia
- Predictors of survival in patients with Parkinson disease
- Differential associations of individual- and neighborhood-level socioeconomic status with mortality in dementia: Findings from the Mayo Clinic Study of Aging